It is with pleasure that we can announce that Clinical Trial Consultants AB (CTC), has been awarded as clinical contract resource organisation (CRO) to execute our upcoming phase I study with our lead candidate PN6047. The study is planned to start in the second quarter of 2022 aiming to investigate safety and tolerability in healthy volunteers. This is a study combining a single ascending dose (SAD) part together with a multiple ascending dose (MAD) part under one common protocol. Following a thorough process in which several European CRO:s submitted their proposals for our evaluation, CTC was awarded based on value for money and an excellent audit. CTC is located in Uppsala, Sweden, and has long experience in conducting early phase studies and fulfilled all our expectations as set-out in our Request for Proposals documentation. We look forward to the collaboration with excitement.
It is with pleasure that we can announce that Clinical Trial Consultants AB (CTC), has been awarded as clinical contract resource organisation (CRO) to execute our upcoming phase I study with our lead candidate PN6047. The study is planned to start in the second quarter of 2022 aiming to investigate safety and tolerability in healthy volunteers. This is a study combining a single ascending dose (SAD) part together with a multiple ascending dose (MAD) part under one common protocol. Following a thorough process in which several European CRO:s submitted their proposals for our evaluation, CTC was awarded based on value for money and an excellent audit. CTC is located in Uppsala, Sweden, and has long experience in conducting early phase studies and fulfilled all our expectations as set-out in our Request for Proposals documentation. We look forward to the collaboration with excitement.
CANADA PATENT GRANT
We are pleased to announce that PharmNovo AB has been granted a patent for our candidate PN6047 in Canada. Previously patent has been granted in the USA, the EU, Japan, Australia and China. Canada was the last major country remaining for PN6047.
Read more →MEET OUR CMO
PharmNovo is pleased to announce the appointment of Olof Breuer MD, PhD, Specialist in Clinical Pharmacology, who will be acting as our Chief medical officer. Olof has over 25 years of experience in Pharmaceutical R&D, where of 17 years within big and small pharmaceutical companies.
Read more →A stronger team
We are pleased to announce that we have hired Jesper Kjerulff, starting on June 1st, to serve as the project leader for the continued development of our candidate compound PN6047 and lead the project into phase 1 clinical trials in Q2 2022.
Read more →In memory of Hans G.
Hans G. Nilsson, PhD (1943–2021), has during a cross country ski trip on a beautiful Sunday in January 2021, unexpectedly left us in grief and mourning.
Read more →
